Analyst Moves: BIIB, X, PFE - Presented by: The Aol. On Network

This morning, Goldman Sachs downgraded shares of Biogen (BIIB) from buy to neutral citing valuation. The stock has reached the firm's $215 price target, leaving less upside for investors.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
BAC $ 14.56 0.23 ▼ 1.56%
AKS $ 4.68 0.31 ▼ 6.21%
FCX $ 14 1.34 ▲ 10.58%
TVIX $ 3.83 0.21 ▲ 5.80%
F $ 13.56 0.53 ▼ 3.76%
AAPL $ 93.74 1.09 ▼ 1.15%
QQQ $ 105.72 0.56 ▼ 0.53%
VALE $ 5.67 0.05 ▲ 0.89%

As of 4/29/2016, 04:15 PM

Latest News Headlines

View All Latest Headlines